Cancer Research The Future of Cancer Research: Science and Patient Impact AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, S.
Right arrow Articles by James, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, S.
Right arrow Articles by James, C. D.
[Cancer Research 63, 723-727, February 1, 2003]
© 2003 American Association for Cancer Research

Tumor Biology

Lanthionine Synthetase Components C-like 2 Increases Cellular Sensitivity to Adriamycin by Decreasing the Expression of P-Glycoprotein through a Transcription-mediated Mechanism1

Soyeon Park and C. David James2

Department of Laboratory Medicine and Pathology and Tumor Biology Program, Mayo Clinic and Foundation, Rochester, Minnesota 55905


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Although the coincidental amplification and accompanying overexpressionof bystander genes that neighbor oncogene targets occur frequently during the development of human tumors, little has been done to investigate the functional or biological consequences of amplified bystander gene overexpression. LANCL2 (LANC-like 2) is a bystander gene that is coamplified and overexpressed with epidermal growth factor receptor in ~20% of all glioblastomas. This gene has also been designated as Testis Adriamycin Sensitivity Protein because it is most highly expressed in testis and its expression has been noted to increase cellular sensitivity to Adriamycin. Because of the latter association, we have examined potential relationships between LANCL2 and the expression of multidrug-resistance (MDR)1, as well as its cognate protein, P-glycoprotein (P-gp), because elevated expression of P-gp is known to increase cell resistance to many cytotoxic drugs, including Adriamycin. Using the Dx5 derivative of MES-SA cells in which P-gp is overexpressed, we show that the level of endogenous P-gp decreases with increased expression of exogenous LanCl-2 and that cells with reduced P-gp show increased sensitivity to Adriamycin. Results from reverse transcription-PCR and MDR1 promoter activity analyses suggest that LanCl-2 transcriptionally suppresses MDR1, and this interpretation of LanCl-2 function is consistent with results from immunofluorescence analysis, which shows that LanCl-2 resides in the nucleus, as well as at the plasma membrane. With respect to this study, our data indicate that LanCl-2 increases cellular sensitivity to Adriamycin by decreasing the expression of P-gp, but more generally, these results indicate that the identification of bystander gene amplification in human tumors can have clinical implications.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Gene amplification is a mechanism for selectively increasing the copy number and expression of specific genes. Amplified MYCN (2p24) in neuroblastoma (1) , CDK43 (12q13–14) in soft tissue sarcomas (2) , and HER2/NEU (17q11–12), as well as CYCD1 (11q13) in breast cancer (3 , 4) , are prime examples of genes whose increased expression promote cell proliferation via an amplification-mediated mechanism.

Results from studies directed at characterizing the size of amplification regions have consistently revealed that the amount of genomic DNA constituting an amplification repeat unit (amplicon) is invariably and considerably larger than that of the target gene itself (5, 6, 7) . As a result, it is not surprising that tumor amplicons generally contain multiple genes. Genes that are amplified as a result of their physical proximity to a target sequence can be considered as coamplified bystanders, and a number of coamplified bystander genes has been identified, including DDX1 at 2p24 (8) , TOPOII{alpha} at 17q11–12 (9) , and GLI at 12q13–14 (7) .

Information has begun to emerge that suggests that the determination of amplicon bystander gene content may be of prognostic and/or therapeutic value to cancer patients, e.g., the coamplification of DDX1 with MYCN has been shown to identify more aggressive neuroblastoma (10) . In breast cancer, the coamplification of TOPOII{alpha} with ERBB-2 has been associated with a more favorable response to chemotherapy (11 , 12) . These results suggest that the occurrence of bystander gene coamplification has significant clinical ramifications. However, it is clear that our understanding of the molecular and biological basis that underlies these clinical observations is meager.

As with other coamplified bystanders, the amplification of LANCL2 results from its proximity to an amplification target, in this case, EGFR at chromosomal region 7p11.2 (13 , 14) . LANCL2 amplification occurs in approximately one-half of glioblastomas with EGFR amplification, or ~20% of all such tumors, and is accompanied by elevated LANCL2 expression (13 , 14) . The consequences of elevated LANCL2 expression are unknown, because there has yet to be any functional analysis performed for this gene’s corresponding protein. The predicted amino acid sequence for LanCl-2 displays limited homology with bacterial LanC family proteins through its seven GXXG repeats, and this homology forms the basis for the name assigned to the human gene (15) . In eukaryotes, the GXXG motif is associated with KH (2) domain proteins that bind single-stranded nucleic acids (16) . Aside from this motif, however, the homology between LanCl-2 and any of the known KH proteins is negligible.

LANCL2 has also been designated as Testis Adriamycin Sensitivity Protein (GenBank accession no. AB035966). As suggested by this name, LANCL2 is most highly expressed in testis, although Northern analysis has revealed its expression in all normal tissues that have been surveyed (14 , 15) . The effect of its expression with respect to cellular drug sensitivity has yet to be investigated in detail. For this reason, in combination with its frequent amplification in glioblastoma, we have examined potential relationships between LanCl-2 expression and cellular sensitivity to Adriamycin, as well as between LanCl-2 and MDR1 expression because its cognate protein, P-gp, is known to increase cellular resistance to many chemotherapeutic agents, including Adriamycin (17) . Our results show that increases in cellular LanCl-2 are accompanied by decreasing expression of P-gp, as well as by increasing cellular sensitivity to Adriamycin. In total, our data suggest that the identification of LANCL2 amplification and attendant overexpression may provide opportunity for targeted therapeutic intervention in the treatment of this cancer. In addition, these results provide further support for the importance of studying bystander gene coamplification in human tumors.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines and Reagents.
The human uterine sarcoma cell line, MES-SA (CRL-1976), and its multidrug-resistant derivative MES-SA/Dx5 (CRL-1977) were purchased from American Type Culture Collection. Cells were maintained in McCoy’s 5a medium supplemented with 10% FCS, 100 units/ml penicillin, and 100 µg/ml streptomycin. Media for maintaining transfectant cells additionally contained G418 at 800 µg/ml.

Cell Transfections.
MES-SA/Dx5 cells were transfected with LANCL2 cDNA cloned into the pcDNA3.1-V5/His (Invitrogen) or empty vector using GenePORTER transfection reagent (Gene Therapy System) following the manufacturer’s protocol. LANCL2 transfectants were selected in the media described above supplemented with 800 µg/ml G418.

Western Blot.
Proteins from whole cell lysates were electrophoresed through 10 or 4–20% gradient gels and transferred to nitrocellulose or polyvinylidene difluoride membranes. Membranes were preincubated with 5% nonfat milk and 0.1% Tween 20 in PBS and subsequently incubated in the same solution with antibody. For detection of V5-tagged LanCl-2, anti-V5 antibody (Invitrogen) was used at 1:5000 dilution. P-gp was detected with C219 (Signet Laboratories) at a concentration of 0.5 µg/ml. Antimouse IgG secondary antibody (Amersham) was used at 1:4000 dilution. Enhanced chemiluminescence reagent (Amersham) was used for chemiluminescence detection.

Cell Proliferation Assay.
Each cell type was plated in hexaplicate at a density of 8,000/well in a 96-well plate. After overnight incubation, Adriamycin was added to concentrations of 0; 10; 50; 500; 1,000; and 10,000 nM. Cells were grown in the presence of drug for 3 days, and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay was performed as described by Gosland et al. (18) . Sample absorbances were determined at 595 nm using a microplate reader (model UV-3550; Bio-Rad).

Immunofluorescence Staining.
Cells were prepared for immunofluorescence confocal microscopy as described previously (19) . Primary antibodies anti-V5 (1:1000 dilution) and MDR Ab-1 (4 µg/ml concentration; Oncogene Research) were used for detection of LanCl-2-V5 and P-gp, respectively. Alexa 488 (LanCl-2-V5) and Alexa 594 (P-gp) were used as secondary according to the manufacturer’s protocol (Molecular Probes). Confocal imaging was performed using a Zeiss LSM510 confocal microscope.

Subcellular Fractionation.
Cells were harvested in PBS and centrifuged at 500 x g for 3 min. Pelleted cells were homogenized in buffer H [0.25 M sucrose, 10 mM HEPES (pH 7.5), and protease inhibitor] and then centrifuged at 1,600 x g for 10 min to obtain a pellet and supernatant. The supernatant was centrifuged at 200,000 x g for 1 h to obtain the cytosolic fraction. The pellet was resuspended in buffer H and homogenized. The sucrose concentration of the homogenate was adjusted to 1.6 M and topped with buffer H. The plasma membrane fraction was obtained after centrifugation at 28,000 rpm for 70 min. The pellet was resuspended in 2.2 M sucrose, 5 mM HEPES, and 3 mM MgCl2 and centrifuged at 41,000 rpm for 1 h to obtain the nuclear fraction.

RT-PCR.
Total cellular RNA was isolated using TRIzol reagent (Invitrogen). RT-PCR for cDNA synthesis was performed using the SuperScript First Strand Synthesis system according to the manufacturer’s specifications (Invitrogen). The primers used for the simultaneous amplification of MDR1 and GAPDH have been described previously (20) . The PCR reaction profile was 1 cycle at 94°C for 2 min for initial denaturation and 25 cycles at 94°C for 30 s, 54°C for 30 s, and 72°C for 30 s with a final extension for 7 min at 72°C. Each reaction product (10 µl) was resolved in a 2% agarose gel and visualized under UV light after ethidium bromide staining. MDR1 and GAPDH band intensities were determined using Multianalyst software (Bio-Rad).

Luciferase Assay.
For MDR1 promoter activity analysis in LANCL2 clonal isolates, cells were seeded into six-well plates at a density of 2–5 x 105 cells/well. After 24 h, LipofectAMINE reagent (Invitrogen) was used to cotransfect cells with 0.5 µg of MDR1 reporter construct (kindly provided by Dr. Kathleen Scotto, Fox Chase Cancer Center; Ref. 21 ) and 1 ng of Renilla luciferase vector pRL-TK (internal control for transfection efficiency). For promoter activity analysis of transient transfectants, cells were cotransfected with either LANCL2 in pcDNA3.1-V5/His or an expression vector and 0.5 µg of EGFR (-777 to -1; Ref. 22 ), MMP1 (-677 to -8; Ref. 23 ), or MDR1 promoter. At 30 h of post-transfection, luciferase activities were measured and normalized against corresponding protein concentrations and/or Renilla luciferase activities.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
LanCl-2 Expression Decreases Cellular P-gp.
To study the effects of LanCl-2 expression on drug sensitivity, we used the sarcoma cell line MES-SA and its multidrug-resistant derivative MES-SA/Dx5 that has elevated P-gp expression (24) . Dx5 cells that were transiently transfected with V5-tagged LANCL2 showed a ~2-fold decrease in P-gp expression (Fig. 1A)Citation . Similar results were observed in long-term transfectant pools, as well as in clonal isolates of LANCL2 transfectants (Fig. 1B)Citation . In fact, results from the clonal isolates suggested an inverse association between LanCl-2 and P-gp expression. No effect of LanCl-2 expression was evident with regard to cellular levels of ß-actin or mitogen-activated protein kinase.



View larger version (55K):
[in this window]
[in a new window]
  		Fig. 1. Exogenous LanCl-2 causes decreased expression of P-gp. Total protein (20 µg) from transient (Dx5-L) or clonal (Dx5-L1, -L2, and -L3) LANCL2 transfectants was electrophoresed through 10% (A) or 4–20% gradient gels (B) and blot transferred to polyvinylidene difluoride membranes, and filters were incubated with anti-V5 or C219 antibodies for LanCl-2-V5 and P-gp detection, respectively. Parental Dx5 cells and Dx5 transfected with empty vector only were used as negative controls.

 
LanCl-2 Expression Increases Cellular Sensitivity to Adriamycin.
The observed decreases in P-gp expression suggest that the LANCL2 transfectants would show increased sensitivity to cytotoxic drugs that are exported by P-gp (17) . To test this possibility, we subjected the clonal LANCL2 transfectants to various concentrations of Adriamycin. Dx5-L2, with the highest LanCl-2 and lowest P-gp expression, was >20-fold more sensitive to Adriamycin as compared with Dx5 cells transfected with vector alone (IC50s of 7 versus 150 nM, respectively: Fig. 2Citation ). Dx5-L1 and -L3, which also show reduced P-gp, were 2–3-fold more sensitive (IC50s of 55 nM) to Adriamycin than vector-transfected Dx5 cells.



View larger version (26K):
[in this window]
[in a new window]
  		Fig. 2. LanCl-2 expression increases Dx5 sensitivity to Adriamycin. Parental Dx5 and Dx5 transfectant derivatives were treated with the indicated concentrations of Adriamycin for 72 h and then subjected to 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Each point on the graph is expressed as the mean ± SD of hexaplicates from representative experiments.

 
LanCl-2 Cellular Distribution.
To address the possibility of a direct interaction between LanCl-2 and P-gp proteins, we conducted coimmunoprecipitation assays. The results did not support a physical association between these proteins, irrespective of the order of use of antibodies for immunoprecipitation and Western blot detection (data not shown). This conclusion was corroborated by immunofluorescence analysis that did not support LanCl-2 and P-gp colocalization, despite each protein showing strong staining at the plasma membrane (Fig. 3A)Citation . Our Western analysis of protein distributions in subcellular fractions indicated that LanCl-2 resides in each of the three cellular compartments: (a) plasma membrane; (b) cytosol; and (c) nucleus (Fig. 3B)Citation . As expected, P-gp was exclusively localized to the plasma membrane in MES-SA/Dx5 and vector-transfected cells (Fig. 3, A and B)Citation . This was also the case for Dx5-L2, although the intensity of membranous P-gp staining in these cells was significantly reduced and therefore consistent with the results from the Western blot analysis of subcellular fractions.



View larger version (79K):
[in this window]
[in a new window]
  		Fig. 3. Subcellular localization of LanCl-2. A, immunofluorescence analysis of V5-tagged LanCl-2 (green) and P-gp (red) using confocal microscopy. LanCl-2-V5 and P-gp were stained with anti-V5 antibody and MDR Ab-1 polyclonal antibody, respectively, in untransfected Dx5 (a, a', a''), vector transfected Dx5 (b, b', b''), and Dx5-L2 (c, c', c''). Secondary antibodies were used as described in "Materials and Methods" (scale bars, 5 µm). B, subcellular localization of LanCl-2 using sucrose gradient fractionation. Ten (plasma membrane) or 20 µg (cytosol and nuclear) of protein from gradient fractions were electrophoresed through a 10% polyacrylamide gel, transferred to a nitrocellulose membrane, and analyzed with antibodies against the indicated proteins. Grb2 and ORC2 were used as cytosolic and nuclear markers, respectively. P, plasma membrane; C, cytosol; N, nucleus.

 
LanCl-2 Suppresses MDR1 Transcription.
To investigate the mechanism by which LanCl-2 reduces cellular P-gp, we used pulse-chase analysis to address potential changes in protein stability. These results, however, indicated no significant difference in P-gp half-life between vector versus LANCL2-transfected Dx5 cells (data not shown). Next, we used RT-PCR to determine whether decreased P-gp expression in LANCL2-transfected cells is associated with decreased cellular mRNA. This analysis revealed decreased MDR1 mRNA in each of the clonal isolates (Fig. 4A)Citation and to an extent that was consistent with the observed decreases in corresponding P-gp protein expression (Fig. 1B)Citation .



View larger version (32K):
[in this window]
[in a new window]
  		Fig. 4. Transcriptional repression of MDR1 in LANCL2-transfected cells. A, RT-PCR analysis of MDR1 mRNA in MES-SA, Dx5, and Dx5 LANCL2 transfectants. Total RNA was subjected to RT-PCR, and cDNA products (MDR1 = 249 bp, GAPDH = 372 bp) were electrophoresed through a 2% agarose gel that was subsequently stained with ethidium bromide. cDNA intensities were measured by scanning densitometry and image analysis using Multianalyst software (Bio-Rad). Numbers below the agarose gel image represent the relative MDR1:GAPDH intensity ratios. RT, reverse transcriptase; M, DNA size markers with length in bp. B, transcriptional suppression of MDR1 in LANCL2-transfected cells. MDR1 promoter-luciferase construct (0.5 µg) and 1 ng of Renilla luciferase (pRL-TK) were cotransfected into MES-SA, Dx5, and Dx5 transfectant derivative cells. At 30-h post-transfection, MDR1 promoter-luciferase and Renilla luciferase activities were determined, with the latter used to normalize MDR1 promoter-luciferase values by accounting for transfection efficiency variations. Normalized values were presented as the mean ± SD of triplicate samples. C, specificity of LANCL2-mediated MDR1 promoter repression. Empty vector (1 µg) or increasing amounts of LANCL2 cDNA were cotransfected into Dx5 cells with MDR1 (0.5 µg), EGFR, or MMP1 promoter (0.5 µg each). At 30-h post-transfection, luciferase activity was measured, normalized against protein concentration, and presented as the mean ± SD of hexaplicate samples.

 
To determine whether the observed decreases in cellular mRNA resulted from reduced MDR1 gene transcription, a luciferase reporter assay was used to compare relative levels of MDR1 promoter activity in MES-SA parental cells, the Dx5 derivative cell line, and in the three Dx5-LANCL2 clonal isolates. This analysis revealed that MDR1 promoter activity was highest in Dx5 cells and Dx5 vector transfectants, with each of these showing approximately seven times the level of MDR1 transcription relative to MES-SA parental cells (Fig. 4B)Citation . Importantly, Dx5-L2, with the highest LanCl-2 expression, demonstrated MDR1 promoter activity comparable with that determined for MES-SA parental cells, indicating a significant level of MDR1 transcriptional suppression. Dx5-L1 and -L3 showed a ~2-fold reduction in MDR1 promoter activity when compared with untransfected Dx5 cells.

To corroborate the repressive effect of LanCl-2 on MDR1 transcription in clonal isolates, we examined Dx5 cells that had been transiently transfected with the MDR1 promoter construct and increasing amounts of LANCL2 cDNA (Fig. 4C)Citation . The results are consistent with MDR1 promoter activity being regulated in a LanCl-2 dose-dependent manner (Fig. 4C)Citation . To test for specificity of MDR1 transcriptional suppression, we examined the effect of LanCl-2 expression on two other promoters: (a) EGFR; and (b) MMP1. The associated results show similar EGFR and MMP1 promoter activities, irrespective of exogenous LanCl-2 expression (Fig. 4C)Citation .


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Our interest in LANCL2 stems from previous studies that revealed this gene as the most frequently coamplified bystander with EGFR (13 , 14) . The occurrence of LANCL2 amplification in only half of glioblastomas with amplified EGFR may be surprising given its proximity to EGFR (~200 kb); however, our work as well as the work of others indicate that tumor amplicons often contain the amplification target gene with relatively little flanking genomic sequence (14 , 25) , and with respect to EGFR amplicons, this is clearly the case.

The cognate protein for LANCL2 has been suggested to sensitize cells to the cytotoxic effects of Adriamycin (GenBank accession no. AB035966), and here we have investigated this possibility by examining the effects of exogenous LANCL2 gene transfer into the well-characterized cell line pair MES-SA and its multidrug-resistant derivative MES-SA/Dx5 (24) . Our results indicate that increasing the expression of LANCL2 does indeed sensitize cells to treatment with Adriamycin and that this effect is associated with decreased expression of P-gp. This relationship is most evident in the case of Dx5-L2 transfectant cells, which show the highest level of LanCl-2 protein expression with an associated 15-fold reduction in expression of P-gp, as well as a corresponding 20-fold increase in sensitivity to Adriamycin (Figs. 1BCitation and 2Citation ).

The effect of LanCl-2 on P-gp expression appears to be at the level of transcription, as indicated by decreased MDR1 promoter activity in LANCL2-transfected cells (Fig. 4, B and C)Citation and supported by results from RT-PCR analysis of MDR1 mRNA levels in the LANCL2 transfectants (Fig. 4A)Citation . Furthermore, the repressive effect of LanCl-2 on transcription shows some degree of specificity for the MDR1 gene promoter because the activities of two other promoters, EGFR and MMP1, were unaffected by LanCl-2 expression (Fig. 4C)Citation . Importantly, we have shown that decreased MDR1 transcription is accompanied by a corresponding decrease in P-gp protein (Fig. 1, A and B)Citation .

Amino acid sequence analysis comparisons show that bacterial LanC protein and LanCl-2 share seven GXXG motifs (15) . This motif is thought to be important for LanC function in antibiotic peptide processing (26) . In eukaryotes, GXXG is a signature motif for KH domains (16) . Structural analysis has proposed the GXXG loop as a DNA/RNA-binding surface (16) . Although flanking regions of the GXXG motifs in LanCl-2 are quite different from the surrounding amino acid residues of GXXG motifs in known KH domain-containing proteins, the presence of this conserved sequence in LanCl-2 suggests that it may function as a single-stranded, nucleic acid-binding protein. Certainly, our data indicating LanCl-2-mediated MDR1 transcriptional suppression, as well as LanCl-2 nuclear localization, provide justification for investigating this possibility in detail. Interestingly, both immunofluorescence and subcellular fractionation analyses (Fig. 3, A and B)Citation indicate that LanCl-2 also resides within the cytoplasmic compartment, with possible concentration of this protein along the inner surface of the plasma membrane. Whether these different cellular populations of LanCl-2 are distinguished through protein modification(s) has yet to be determined.

Bystander gene coamplification has been demonstrated for other loci in other types of cancer (7, 8, 9) , and results from recent studies suggest that the determination of bystander gene coamplification may be of relevance to the prognosis and treatment of cancer patients (11 , 12) . In the present study, we have shown that the introduction of exogenous LANCL2, a bystander gene that is coamplified with EGFR in glioblastoma, causes increased cellular sensitivity to an anticancer drug. The implications of this investigation are therefore analogous to those showing that the coamplification of TOPOII{alpha} with ERBB2 results in altered cellular sensitivity to topoisomerase II inhibitors (11 , 12) . A similar, albeit inverse, concept has been advanced for the frequent codeletion of the methylthioadenosine phosphorylase gene with CDKN2A, which can be exploited for selective chemotherapy with de novo purine synthesis inhibitors (27) . In point of contrast, however, frequent homozygous deletions of genes other than CDKN2A have yet to be demonstrated in human tumors, whereas a substantial body of literature attests to the existence of multiple amplification targets in human cancer (7, 8, 9) . Our results, combined with the results from studies published previously (10, 11, 12) , support the importance for detailed characterization of tumor cell amplicons and for determining the functional consequences associated with the coamplification of individual bystander genes.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by National Cancer Institute Grant CA85779. Back

2 To whom requests for reprints should be addressed, at Mayo Clinic, 200 First Street, SW Hilton Bldg, Room 820-D, Rochester, MN 55905. Phone: (507) 284-8989; Fax: (507) 266-5193; E-mail: james.david{at}mayo.edu Back

3 The abbreviations used are: CDK, cyclin-dependent kinase; KH, K homology; P-gp, P-glycoprotein; EGFR, epidermal growth factor receptor; LANCL2, LANC-like-2; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase; MDR, multidrug-resistance. Back

Received 9/25/02. Accepted 11/27/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Schwab M., Alitalo K., Klempnauer K. H., Varmus H. E., Bishop J. M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (Lond.), 305: 245-248, 1983.[Medline]
  2. Khatib Z. A., Matsushime H., Valentine M., Shapiro D. N., Sherr C. J., Look A. T. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53: 5535-5541, 1993.[Abstract/Free Full Text]
  3. King C. R., Kraus M. H., Aaronson S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (Wash. DC), 229: 974-976, 1985.[Abstract/Free Full Text]
  4. Schuuring E., Verhoeven E., Mooi W. J., Michalides R. J. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene, 7: 355-361, 1992.[Medline]
  5. Tanigami A., Tokino T., Takita K., Ueda M., Kasumi F., Nakamura Y. Detailed analysis of an amplified region at chromosome 11q13 in malignant tumors. Genomics, 13: 21-24, 1992.[Medline]
  6. Tomasetto C., Regnier C., Moog-Lutz C., Mattei M. G., Chenard M. P., Lidereau R., Basset P., Rio M. C. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11–q21.3 region of chromosome 17. Genomics, 28: 367-376, 1995.[Medline]
  7. Forus A., Florenes V. A., Maelandsmo G. M., Meltzer P. S., Fodstad O., Myklebost O. Mapping of amplification units in the q13–14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ., 4: 1065-1070, 1993.[Abstract]
  8. Amler L. C., Schurmann J., Schwab M. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma. Genes Chromosomes Cancer, 15: 134-137, 1996.[Medline]
  9. Smith K., Houlbrook S., Greenall M., Carmichael J., Harris A. L. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene, 8: 933-938, 1993.[Medline]
  10. George R. E., Kenyon R., McGuckin A. G., Kohl N., Kogner P., Christiansen H., Pearson A. D., Lunec J. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur. J. Cancer, 33: 2037-2042, 1997.
  11. Jarvinen T. A., Tanner M., Rantanen V., Barlund M., Borg A., Grenman S., Isola J. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol., 156: 839-847, 2000.[Abstract/Free Full Text]
  12. Coon J. S., Marcus E., Gupta-Burt S., Seelig S., Jacobson K., Chen S., Renta V., Fronda G., Preisler H. D. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res., 8: 1061-1067, 2002.[Abstract/Free Full Text]
  13. Wang X. Y., Smith D. I., Frederick L., James C. D. Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene, 16: 191-195, 1998.[Medline]
  14. Eley G. D., Reiter J. L., Pandita A., Park S., Jenkins R. B., Maihle N. J., James C. D. A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neuro-Oncology, 4: 86-94, 2002.[Abstract]
  15. Mayer H., Pongratz M., Prohaska R. Molecular cloning, characterization, and tissue-specific expression of human LANCL2, a novel member of the LanC-like protein family. DNA Seq., 12: 161-166, 2001.[Medline]
  16. Musco G., Stier G., Joseph C., Castiglione Morelli M. A., Nilges M., Gibson T. J., Pastore A. Three-dimensional structure and stability of the KH domain: molecular insights into the fragile X syndrome. Cell, 85: 237-245, 1996.[Medline]
  17. Ambudkar S. V., Dey S., Hrycyna C. A., Ramachandra M., Pastan I., Gottesman M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39: 361-398, 1999.[Medline]
  18. Gosland M. P., Lum B. L., Sikic B. I. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res., 49: 6901-6905, 1989.[Medline]
  19. Orth J. D., Krueger E. W., Cao H., McNiven M. A. The large GTPase dynamin regulates actin comet formation and movement in living cells. Proc. Natl. Acad. Sci. USA, 99: 167-172, 2002.[Abstract/Free Full Text]
  20. Chuang S. E., Doong S. L., Lin M. T., Cheng A. L. Tax of the human T-lymphotropic virus type I transactivates promoter of the MDR-1 gene. Biochem. Biophys. Res. Commun., 238: 482-486, 1997.[Medline]
  21. Jin S., Scotto K. W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol., 18: 4377-4384, 1998.[Abstract/Free Full Text]
  22. Deb S. P., Munoz R. M., Brown D. R., Subler M. A., Deb S. Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene, 9: 1341-1349, 1994.[Medline]
  23. Watabe T., Yoshida K., Shindoh M., Kaya M., Fujikawa K., Sato H., Seiki M., Ishii S., Fujinaga K. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int. J. Cancer, 77: 128-137, 1998.[Medline]
  24. Harker W. G., Sikic B. I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res., 45: 4091-4096, 1985.[Abstract/Free Full Text]
  25. Reiter J. L., Brodeur G. M. High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Genomics, 32: 97-103, 1996.[Medline]
  26. Kupke T., Gotz F. Expression, purification, and characterization of EpiC, an enzyme involved in the biosynthesis of the lantibiotic epidermin, and sequence analysis of Staphylococcus epidermidis epiC mutants. J. Bacteriol., 178: 1335-1340, 1996.[Abstract/Free Full Text]
  27. Hori Y., Hori H., Yamada Y., Carrera C. J., Tomonaga M., Kamihira S., Carson D. A., Nobori T. The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int. J. Cancer, 75: 51-56, 1998.[Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, S.
Right arrow Articles by James, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, S.
Right arrow Articles by James, C. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online